A carregar...
Update on the role of brentuximab vedotin in classical Hodgkin lymphoma
Brentuximab vedotin (BV) is an effective and well-tolerated treatment for patients with classical Hodgkin lymphoma (HL). It was initially approved by the US FDA for the treatment of HL after failure of autologous hematopoietic stem cell transplant (autoHSCT) or after failure of at least two prior li...
Na minha lista:
| Publicado no: | Ther Adv Hematol |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6130098/ https://ncbi.nlm.nih.gov/pubmed/30210755 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620718786833 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|